BPC-157: Mechanism, Research, and Use Cases

As of early 2026, no completed, peer-reviewed, randomized controlled trials of BPC-157 in humans have been published. Sikiric's group at the University of Zagreb has published extensively in rodent models, but no Phase 1/2/3 human data exist in the literature. Investigators at PL10 Therapeutics have registered clinical trials studying a related compound (PL14736, an oral BPC-157 analog) in Crohn's disease, but results have not been published.

WADA added BPC-157 to its S0 (Non-Approved Substances) list in 2023. S0 prohibits any pharmacological substance that has no current approval by a governmental regulatory health authority for human therapeutic use. WADA added BPC-157 because of increasing use by athletes, not because of established performance-enhancing efficacy. The prohibition does not require proven doping benefit — only that the substance lacks regulatory approval.

Reconstitute lyophilized BPC-157 with bacteriostatic water (0.9% benzyl alcohol). Add water slowly down the vial wall; swirl gently. Dissolves readily at 500 mcg/mL to 1 mg/mL concentrations. Solution should be clear and colorless. Store reconstituted solution at 2–8°C for up to 30 days. Some researchers prefer acetic acid (0.1%) as a diluent, which is compatible with BPC-157 for research use.

Preclinical studies have evaluated: intraperitoneal injection, subcutaneous injection, intragastric (oral) administration, and local/topical application. Notably, BPC-157 appears active across all these routes in preclinical models — including oral, which is unusual for peptides (most are degraded in GI tract). This oral stability (due to resistance to gastric enzymes) is proposed as a key feature of BPC-157.

Preclinical mechanistic data implicate: (1) FAK-paxillin pathway activation promoting fibroblast and tenocyte migration and proliferation; (2) VEGFR2 upregulation driving angiogenesis (new blood vessel formation to the healing tendon); (3) upregulation of early growth response protein 1 (Egr-1), a transcription factor driving tendon-specific matrix gene expression; (4) normalization of NO system activity in ischemic tendon tissue.

TB-500 (a fragment of thymosin beta-4) and BPC-157 are often studied in combination by researchers interested in tissue repair. The compounds have distinct and potentially complementary mechanisms: BPC-157 primarily targets angiogenesis and FAK/paxillin pathways, while TB-500 (Tβ4) acts via actin polymerization regulation and VEGF-mediated effects. Combination protocols are not supported by published clinical data — all combination research is preclinical or anecdotal.

Lyophilized BPC-157 is stable for 24+ months at −20°C in properly sealed, desiccated vials. The peptide sequence (15 amino acids) has no disulfide bonds, which reduces oxidative degradation risk. Primary stability concerns are moisture absorption (use desiccant packs during storage) and repeated thermal cycling. After reconstitution, use within 28–30 days when stored at 2–8°C.

Preclinical models where BPC-157 showed efficacy include: NSAID-induced gastric ulcers, alcohol-induced gastric lesions, short bowel syndrome (intestinal anastomosis healing), inflammatory bowel disease (acetic acid colitis model), fistula healing, and cytoprotection against chemotherapy-induced intestinal damage. The range of GI effects has driven interest in oral BPC-157 analogs for human GI disease, though human data remain unpublished.